18 F-FDG Uptake on PET/CT in Symptomatic versus Asymptomatic Carotid Disease: a Meta-Analysis

Bonow, 2002, World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic, Circulation, 106, 1602, 10.1161/01.CIR.0000035036.22612.2B Meschia, 2015, Time from symptoms to carotid endarterectomy or stenting and perioperative risk, Stroke, 46, 3540, 10.1161/STROKEAHA.115.011123 Naylor, 2018, Editor's choice – management of atherosclerotic carotid and vertebral artery disease: 2017 clinical practice guidelines of the European Society for Vascular Surgery (ESVS), Eur J Vasc Endovasc Surg, 55, 3, 10.1016/j.ejvs.2017.06.021 Naylor, 2014, Identifying the high-risk carotid plaque, J Cardiovasc Surg (Torino), 55, 11 Nagel, 1999, Vascular endothelial cells respond to spatial gradients in fluid shear stress by enhanced activation of transcription factors, Arterioscler Thromb Vasc Biol, 19, 1825, 10.1161/01.ATV.19.8.1825 Gimbrone, 2000, Endothelial dysfunction, hemodynamic forces, and atherogenesis, Ann NY Acad Sci, 902, 230, 10.1111/j.1749-6632.2000.tb06318.x Libby, 2002, Inflammation and atherosclerosis, Circulation, 105, 1135, 10.1161/hc0902.104353 Leppänen, 2006, ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo, Atherosclerosis, 188, 323, 10.1016/j.atherosclerosis.2005.11.017 Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ, 339, b2700, 10.1136/bmj.b2700 Higgins, 2011 Rudd, 2002, Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography, Circulation, 105, 2708, 10.1161/01.CIR.0000020548.60110.76 Davies, 2005, Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging, Stroke, 36, 2642, 10.1161/01.STR.0000190896.67743.b1 Arauz, 2007, Carotid plaque inflammation detected by 18F-fluorodeoxyglucose-positron emission tomography. Pilot study, Clin Neurol Neurosurg, 109, 409, 10.1016/j.clineuro.2007.02.012 Kwee, 2011, Potential of integrated [18F] fluorodeoxyglucose positron-emission tomography/CT in identifying vulnerable carotid plaques, AJNR Am J Neuroradiol, 32, 950, 10.3174/ajnr.A2381 Grandpierre, 2011, Arterial foci of F-18 fluorodeoxyglucose are associated with an enhanced risk of subsequent ischemic stroke in cancer patients: a case-control pilot study, Clin Nucl Med, 36, 85, 10.1097/RLU.0b013e318203bb42 Marnane, 2012, Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence, Ann Neurol, 71, 709, 10.1002/ana.23553 Muller, 2014, 18FDG-PET-CT: an imaging biomarker of high-risk carotid plaques. Correlation to symptoms and microembolic signals, Stroke, 45, 3561, 10.1161/STROKEAHA.114.006488 Taqueti, 2014, Increased microvascularisation and vessel permeability associate with active inflammation in human atheromata, Circ Cardiovasc Imaging, 7, 920, 10.1161/CIRCIMAGING.114.002113 Shaikh, 2014, Comparison of fluorodeoxyglucose uptake in symptomatic carotid artery and stable femoral artery plaques, Br J Surg, 101, 363, 10.1002/bjs.9403 Skagen, 2015, Carotid plaque inflammation assessed with (18)F-FDG PET/CT is higher in symptomatic compared with asymptomatic patients, Int J Stroke, 10, 730, 10.1111/ijs.12430 Quirce, 2016, New insight of functional molecular imaging into the atheroma biology: 18F-NaF and 18F-FDG in symptomatic and asymptomatic carotid plaques after recent CVA. Preliminary results, Clin Physiol Funct Imaging, 36, 499, 10.1111/cpf.12254 Vesey, 2017, 18F-Fluoride and 18F-fluorodeoxyglucose positron emission tomography after transient ischemic attack of minor ischaemic stroke: case-control study, Circ Cardiovasc Imaging, 10, 1, 10.1161/CIRCIMAGING.116.004976 Tarkin, 2017, Detection of atherosclerotic inflammation by 68Ga-DOTATATE PET compared to (18F) FDG PET imaging, J Am Coll Cardiol, 69, 1774, 10.1016/j.jacc.2017.01.060 Joshi, 2017, Vascular imaging with 18F-fluorodeoxyglucose positron emission tomography is influenced by hypoxia, J Am Coll Cardiol, 69, 1873, 10.1016/j.jacc.2017.01.050 Aboyans, 2018, Editor's choice – 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery, Eur J Vasc Endovasc Surg, 55, 305, 10.1016/j.ejvs.2017.07.018 Barnett, 1998, Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators, N Engl J Med, 339, 1415, 10.1056/NEJM199811123392002 Li, 2016, Quantitative assessment of atherosclerotic plaques on (18)F-FDG PET/MRI: comparison with a PET/CT hybrid system, Eur J Nucl Mol Imaging, 43, 1503, 10.1007/s00259-016-3308-6 Huibers, 2015, Non-invasive carotid artery imaging to identify the vulnerable plaque: current status and future goals, Eur J Vasc Endovasc Surg, 50, 563, 10.1016/j.ejvs.2015.06.113 Rominger, 2009, 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease, J Nucl Med, 10, 1611, 10.2967/jnumed.109.065151 van der Valk, 2016, Thresholds for arterial wall inflammation quantified by 18F-FDG PET imaging: implications for vascular interventional studies, JACC Cardiovasc Imaging, 9, 1198, 10.1016/j.jcmg.2016.04.007 Bucci, 2014, Validation of FDG uptake in the arterial wall as an imaging biomarker of atherosclerotic plaques with 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT), J Neuroimaging, 24, 117, 10.1111/j.1552-6569.2012.00740.x Bucerius, 2016, Position paper of the cardiovascular committee of the european association of nuclear medicine (EANM) on PET imaging of atherosclerosis, Eur J Nucl Med Mol Imaging, 43, 780, 10.1007/s00259-015-3259-3 Joshi, 2014, 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial, Lancet, 383, 705, 10.1016/S0140-6736(13)61754-7